Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer carbonate for chronic kidney disease with residual proteinuria
2012-005416-26Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Apr 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sevelamer carbonate in chronic kidney disease (CKD) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: 24-hour urinary protein excretion. Started Apr 2013; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-005416-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005416-26.